BACKGROUND: Hemostatic benefits of platelet transfusions in thienopyridine-treated acute coronary syndrome (ACS) patients may be compromised by residual metabolite in circulation. OBJECTIVES: To estimate the earliest time after a prasugrel loading-dose when added platelets are no longer inhibited by prasugrel's active metabolite. METHODS: Baseline platelet reactivity of healthy subjects (n=25, 30 ± 5 years, 68% male) on ASA 325 mg was tested using maximum platelet aggregation (MPA, ADP 20 μm) and VerifyNow(®) P2Y12 and was followed by a 60 mg prasugrel loading-dose. At 2, 6, 12 and 24 h post-dose, fresh concentrated platelets from untreated donors were added ex-vivo to subjects' blood, raising platelet counts by 0% (control), 40%, 60% and 80%. To estimate the earliest time when prasugrel's active metabolite's inhibitory effect on the added platelets ceases, platelet function in supplemented samples was compared across time-points to identify the time when effect of supplementation on platelet function stabilized (i.e. the increase in platelet reactivity was statistically similar to that at the next time-point). RESULTS: Supplemented samples showed concentration-dependent increases in platelet reactivity vs. respective controls by both MPA and VerifyNow(®) at all assessment time-points. For each supplementation level, platelet reactivity showed a sharp increase from 2 to 6 h but was stable (P=NS) between 6 and 12 h. CONCLUSIONS: The earliest measured time when supplemented platelets were not inhibited by circulating active metabolite of prasugrel was 6 h after a prasugrel loading-dose. These findings may have important implications for prasugrel-treated ACS patients requiring platelet transfusions during surgery.
BACKGROUND: Hemostatic benefits of platelet transfusions in thienopyridine-treated acute coronary syndrome (ACS) patients may be compromised by residual metabolite in circulation. OBJECTIVES: To estimate the earliest time after a prasugrel loading-dose when added platelets are no longer inhibited by prasugrel's active metabolite. METHODS: Baseline platelet reactivity of healthy subjects (n=25, 30 ± 5 years, 68% male) on ASA 325 mg was tested using maximum platelet aggregation (MPA, ADP 20 μm) and VerifyNow(®) P2Y12 and was followed by a 60 mg prasugrel loading-dose. At 2, 6, 12 and 24 h post-dose, fresh concentrated platelets from untreated donors were added ex-vivo to subjects' blood, raising platelet counts by 0% (control), 40%, 60% and 80%. To estimate the earliest time when prasugrel's active metabolite's inhibitory effect on the added platelets ceases, platelet function in supplemented samples was compared across time-points to identify the time when effect of supplementation on platelet function stabilized (i.e. the increase in platelet reactivity was statistically similar to that at the next time-point). RESULTS: Supplemented samples showed concentration-dependent increases in platelet reactivity vs. respective controls by both MPA and VerifyNow(®) at all assessment time-points. For each supplementation level, platelet reactivity showed a sharp increase from 2 to 6 h but was stable (P=NS) between 6 and 12 h. CONCLUSIONS: The earliest measured time when supplemented platelets were not inhibited by circulating active metabolite of prasugrel was 6 h after a prasugrel loading-dose. These findings may have important implications for prasugrel-treated ACS patients requiring platelet transfusions during surgery.
Authors: Frederick G Kushner; Mary Hand; Sidney C Smith; Spencer B King; Jeffrey L Anderson; Elliott M Antman; Steven R Bailey; Eric R Bates; James C Blankenship; Donald E Casey; Lee A Green; Judith S Hochman; Alice K Jacobs; Harlan M Krumholz; Douglass A Morrison; Joseph P Ornato; David L Pearle; Eric D Peterson; Michael A Sloan; Patrick L Whitlow; David O Williams Journal: Circulation Date: 2009-11-18 Impact factor: 29.690
Authors: R Scott Wright; Jeffrey L Anderson; Cynthia D Adams; Charles R Bridges; Donald E Casey; Steven M Ettinger; Francis M Fesmire; Theodore G Ganiats; Hani Jneid; A Michael Lincoff; Eric D Peterson; George J Philippides; Pierre Theroux; Nanette K Wenger; James Patrick Zidar; Jeffrey L Anderson; Cynthia D Adams; Elliott M Antman; Charles R Bridges; Robert M Califf; Donald E Casey; William E Chavey; Francis M Fesmire; Judith S Hochman; Thomas N Levin; A Michael Lincoff; Eric D Peterson; Pierre Theroux; Nanette K Wenger; R Scott Wright Journal: J Am Coll Cardiol Date: 2011-03-28 Impact factor: 24.094
Authors: Sasha Koul; J Gustav Smith; Fredrik Scherstén; Stefan James; Bo Lagerqvist; David Erlinge Journal: Eur Heart J Date: 2011-06-30 Impact factor: 29.983
Authors: Matthew J Price; James S Walder; Brian A Baker; Darell E Heiselman; Joseph A Jakubowski; Douglas K Logan; Kenneth J Winters; Wei Li; Dominick J Angiolillo Journal: J Am Coll Cardiol Date: 2012-06-19 Impact factor: 24.094
Authors: David S Small; Ying G Li; C Steven Ernest; John H April; Nagy A Farid; Christopher D Payne; Kenneth J Winters; Shashank Rohatagi; Lan Ni Journal: J Clin Pharmacol Date: 2010-04-21 Impact factor: 3.126
Authors: Stephen D Wiviott; Dietmar Trenk; Andrew L Frelinger; Michelle O'Donoghue; Franz-Josef Neumann; Alan D Michelson; Dominick J Angiolillo; Hanoch Hod; Gilles Montalescot; Debra L Miller; Joseph A Jakubowski; Richard Cairns; Sabina A Murphy; Carolyn H McCabe; Elliott M Antman; Eugene Braunwald Journal: Circulation Date: 2007-12-03 Impact factor: 29.690
Authors: Lisa Schoener; Stefanie Jellinghaus; Bernhardt Richter; Christian Pfluecke; Georg Ende; Marian Christoph; Silvio Quick; Tobias Loehn; Uwe Speiser; David M Poitz; Johannes Mierke; Ruth H Strasser; Karim Ibrahim Journal: Clin Res Cardiol Date: 2017-06-26 Impact factor: 5.460
Authors: Constance C F M J Baaten; Leo F Veenstra; Rick Wetzels; Johanna P van Geffen; Frauke Swieringa; Susanne M de Witt; Yvonne M C Henskens; Harry Crijns; Sven Nylander; J J J van Giezen; Johan W M Heemskerk; Paola E J van der Meijden Journal: Haematologica Date: 2015-06-25 Impact factor: 9.941
Authors: M Urooj Zafar; Donald A Smith; Usman Baber; Samantha Sartori; Kevin Chen; David W Lam; Carlos A Linares-Koloffon; Juan Rey-Mendoza; Gustavo Jimenez Britez; Gines Escolar; Valentin Fuster; Juan J Badimon Journal: Circ Cardiovasc Interv Date: 2017-08 Impact factor: 6.546